TEL AVIV, Israel, Mar. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of the liver-targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, announced today that its senior management will provide a corporate update in upcoming investor conferences, including the Roth 30th Annual Conference, the H.C. Wainwright 2nd Annual NASH Investor Conference and the Oppenheimer 28th Annual Healthcare Conference.
Roth 30th Annual Conference:
Date: Monday, March 12
Time: 2:30 pm Pacific Time
Location: GREEN - SALON 3, The Ritz-Carlton, Laguna Niguel, CA
H.C. Wainwright 2nd Annual NASH Investor Conference:
Date: Monday, March 19
Time: 10:00 am Eastern Time
Location: The St. Regis Hotel, New York, NY
Oppenheimer 28th Annual Healthcare Conference:
Date: Tuesday, March 20
Time: 09:45 am Estern Time
Location: Track 2 room, The Westin New York Grand Central, New York City
About Aramchol™ and Non-alcoholic Steatohepatitis (NASH)
Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplantation in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis, liver cancer and end-stage liver disease related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on ClinicalTrials.gov identifier: NCT02279524.
SOURCE Galmed Pharmaceuticals Ltd.